Adenoma and advanced neoplasia detection rates increase from 45 years of age.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
28 Jan 2019
Historique:
received: 08 11 2018
revised: 23 12 2018
accepted: 27 12 2018
entrez: 1 2 2019
pubmed: 1 2 2019
medline: 6 4 2019
Statut: ppublish

Résumé

Colonoscopy is considered a valid primary screening tool for colorectal cancer (CRC). The decreasing risk of CRC observed in patients undergoing colonoscopy is correlated with the adenoma detection rate (ADR). Due to the fact that screening programs usually start from the age of 50, very few data are available on the risk of adenoma between 40 and 49 years. However, the incidence of CRC is increasing in young populations and it is not uncommon in routine practice to detect adenomas or even advanced neoplasia during colonoscopy in patients under 50 years. To compare the ADR and advanced neoplasia detection rate (ANDR) according to age in a large series of patients during routine colonoscopy. All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were as follows: patients scheduled for partial colonoscopy or interventional colonoscopy (for stent insertion or stenosis dilation). Colonoscopies were performed in our unit by a team of 30 gastroenterologists in 2016. We determined the ADR and ANDR in each age group in the whole population and in the population with an average risk of CRC (excluding patients with personal or family history of advanced adenoma or cancer). 6027 colonoscopies were performed in patients with a median age of 57 years (range, 15-96). The ADR and ANDR were 28.6% and 9.7%, respectively, in the whole population. When comparing patients aged 40-44 ( This study shows a significant two-fold increase in the ADR and ANDR in patients aged 45 years and over.

Sections du résumé

BACKGROUND BACKGROUND
Colonoscopy is considered a valid primary screening tool for colorectal cancer (CRC). The decreasing risk of CRC observed in patients undergoing colonoscopy is correlated with the adenoma detection rate (ADR). Due to the fact that screening programs usually start from the age of 50, very few data are available on the risk of adenoma between 40 and 49 years. However, the incidence of CRC is increasing in young populations and it is not uncommon in routine practice to detect adenomas or even advanced neoplasia during colonoscopy in patients under 50 years.
AIM OBJECTIVE
To compare the ADR and advanced neoplasia detection rate (ANDR) according to age in a large series of patients during routine colonoscopy.
METHODS METHODS
All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were as follows: patients scheduled for partial colonoscopy or interventional colonoscopy (for stent insertion or stenosis dilation). Colonoscopies were performed in our unit by a team of 30 gastroenterologists in 2016. We determined the ADR and ANDR in each age group in the whole population and in the population with an average risk of CRC (excluding patients with personal or family history of advanced adenoma or cancer).
RESULTS RESULTS
6027 colonoscopies were performed in patients with a median age of 57 years (range, 15-96). The ADR and ANDR were 28.6% and 9.7%, respectively, in the whole population. When comparing patients aged 40-44 (
CONCLUSION CONCLUSIONS
This study shows a significant two-fold increase in the ADR and ANDR in patients aged 45 years and over.

Identifiants

pubmed: 30700941
doi: 10.3748/wjg.v25.i4.447
pmc: PMC6350166
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-456

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.

Références

Gut. 2000 Aug;47(2):251-5
pubmed: 10896917
Ann Intern Med. 2003 Dec 16;139(12):1034-5
pubmed: 14678923
Clin Gastroenterol Hepatol. 2004 Jan;2(1):72-7
pubmed: 15017635
Gastroenterology. 2004 Jun;126(7):1674-80
pubmed: 15188160
N Engl J Med. 2006 Nov 2;355(18):1863-72
pubmed: 17079760
JAMA. 2008 Dec 17;300(23):2765-78
pubmed: 19088354
Gastrointest Endosc. 2009 Mar;69(3 Pt 2):620-5
pubmed: 19136102
Int J Cancer. 2009 May 15;124(10):2406-15
pubmed: 19142968
Am J Gastroenterol. 2009 Mar;104(3):739-50
pubmed: 19240699
Gastrointest Endosc. 2010 Oct;72(4):686-92
pubmed: 20883845
N Engl J Med. 2012 Feb 23;366(8):687-96
pubmed: 22356322
Am J Gastroenterol. 2012 Sep;107(9):1315-29; quiz 1314, 1330
pubmed: 22710576
Eur J Cancer Prev. 2013 Nov;22(6):492-505
pubmed: 23591454
N Engl J Med. 2013 Sep 19;369(12):1106-14
pubmed: 24047060
Mayo Clin Proc. 2014 Feb;89(2):216-24
pubmed: 24393412
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17
pubmed: 24639052
N Engl J Med. 2014 Apr 3;370(14):1298-306
pubmed: 24693890
BMJ. 2014 Apr 09;348:g2467
pubmed: 24922745
Dig Dis. 2015;33(1):19-27
pubmed: 25531493
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Dig Dis Sci. 2016 Oct;61(10):3026-3030
pubmed: 27278956
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Endoscopy. 2017 Apr;49(4):378-397
pubmed: 28268235
Gastroenterology. 2017 Jul;153(1):307-323
pubmed: 28600072
World J Gastroenterol. 2017 May 28;23(20):3632-3642
pubmed: 28611516
World J Gastroenterol. 2017 Jul 28;23(28):5086-5096
pubmed: 28811705
World J Surg Oncol. 2017 Aug 23;15(1):159
pubmed: 28835275
J Gastrointest Surg. 2017 Nov;21(11):1898-1905
pubmed: 28842810
N Engl J Med. 1993 Dec 30;329(27):1977-81
pubmed: 8247072
N Engl J Med. 1993 May 13;328(19):1365-71
pubmed: 8474513

Auteurs

David Karsenti (D)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France. karsenti@club-internet.fr.

Gaelle Tharsis (G)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Pascal Burtin (P)

Digestive Endoscopy Unit, Institut Gustave Roussy, Villejuif 94800, France.

Franck Venezia (F)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Gilles Tordjman (G)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Agnès Gillet (A)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Joelle Samama (J)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Karine Nahon-Uzan (K)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Philippe Cattan (P)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Maryan Cavicchi (M)

Digestive Endoscopy Unit, Clinique Paris-Bercy, Charenton-le-Pont 94220, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH